Hatim Husain

Nov 22, 2024 | targetedonc.com | Hatim Husain

November 22, 2024Panelist discusses how the future treatment landscape for EGFR-mutant advanced non–small cell lung cancer is evolving to address current unmet needs and offers clinical pearls to community oncologists for optimizing patient care in this rapidly changing field. Video content above is prompted by the following:What do you see as the future treatment landscape for EGFR-mutant advanced non–small cell lung cancer (NSCLC)?

Nov 15, 2024 | targetedonc.com | Hatim Husain

November 15, 2024Hatim Husain, MD, discusses how the implementation of proactive prophylaxis strategies for patients taking amivantamab, including prophylactic antibiotics, good skin hygiene, and insights from the phase 2 COCOON study, can help manage potential adverse effects and improve treatment outcomes. Video content above is prompted by the following:What proactive prophylaxis strategies have you integrated into your practice for patients taking amivantamab?

Nov 13, 2024 | cancernetwork.com | Hatim Husain |Karen L. Reckamp

November 13, 2024By OncologyONCOLOGY Vol 38, Issue 11Pages: 444-446Personalized therapy for non–small cell lung cancer has evolved significantly with the advent of comprehensive molecular testing.

Nov 8, 2024 | targetedonc.com | Hatim Husain

Video content above is prompted by the following:The second interim overall survival data from MARIPOSA-2 were presented at the European Society for Medical Oncology Congress 2024. Please briefly discuss the updated data and the implications for second-line therapy for those currently receiving osimertinib, particularly when osimertinib is continued with platinum-based chemotherapy after resistance to osimertinib is noted.

Nov 1, 2024 | targetedonc.com | Hatim Husain

Video content above is prompted by the following:An early analysis of the mechanisms of acquired resistance to first-line treatment with amivantamab plus lazertinib vs osimertinib was presented at the European Society for Medical Oncology Congress 2024. Please discuss the findings and their implications on the frontline treatment decisions for patients with EGFR mutations or MET amplification.